Alessandro Cuomo

SILAC-based proteomic analysis to dissect the "histone modification signature" of human breast cancer cells.

Yin Yang 1 extends the Myc-related transcription factors network in embryonic stem cells.

Mass spectrometry-based proteomics for the analysis of chromatin structure and dynamics.

Cell reprogramming requires silencing of a core subset of polycomb targets.

Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity.

SILAC-Based Quantitative Strategies for Accurate Histone Posttranslational Modification Profiling Across Multiple Biological Samples.

PARP14 Controls the Nuclear Accumulation of a Subset of Type I IFN-Inducible Proteins.

Zc3h10 is a novel mitochondrial regulator.

Alternative digestion approaches improve histone modification mapping by mass spectrometry in clinical samples.

hmSEEKER: Identification of hmSILAC Doublets in MaxQuant Output Data.

Proteomics profiling of arginine methylation defines PRMT5 substrate specificity.

PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin.

Biochemical and Computational Approaches for the Large-Scale Analysis of Protein Arginine Methylation by Mass Spectrometry.

FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy.

Long non-coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation.

Software Options for the Analysis of MS-Proteomic Data.

Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response.

ProMetheusDB: An In-Depth Analysis of the High-Quality Human Methyl-proteome.

Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors.

Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2.

Serum proteomics profiling identifies a preliminary signature for the diagnosis of early-stage lung cancer.